Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have earned a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $7.50.

GANX has been the topic of several recent analyst reports. Weiss Ratings cut shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. BTIG Research reaffirmed a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a research report on Tuesday, June 30th. Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, July 1st. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP grew its position in shares of Gain Therapeutics by 849.3% in the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock worth $5,353,000 after buying an additional 1,487,186 shares during the last quarter. Potomac Capital Management Inc. purchased a new position in shares of Gain Therapeutics in the fourth quarter worth $3,252,000. Jane Street Group LLC boosted its holdings in Gain Therapeutics by 234.5% in the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after purchasing an additional 169,878 shares during the last quarter. LPL Financial LLC purchased a new position in shares of Gain Therapeutics in the fourth quarter worth approximately $343,000. Finally, State Street Corp grew its holdings in Gain Therapeutics by 72.9% during the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares during the period. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $1.63 on Tuesday. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34. The firm has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $2.00. The company has a market capitalization of $69.52 million, a PE ratio of -2.81 and a beta of 0.15. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). During the same quarter last year, the company posted ($0.16) EPS. On average, sell-side analysts forecast that Gain Therapeutics will post -0.54 EPS for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.